# Early phase 1 glioblastoma trials recruiting: 24 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 24 trials in early phase 1 for glioblastoma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Early phase 1 glioblastoma trials: 24 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/early-phase-1/glioblastoma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 24
- Recruiting or not yet: 24
- Read on: November 19, 2026

## Trials

The 24 newest of 24, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 30, 2026 | NCT07908147 | Biomarker-guided RAdiation-deferring Treatment in Younger GBM Patients - Pilot Study | Olivia Newton-John Cancer Research Institute | Early phase 1 | Not yet recruiting | IDH Wildtype Glioblastoma, Glioblastoma (GBM) | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908147) |
| October 20, 2026 | NCT07884344 | Window of Opportunity Study of Lixumistat in Patients With Newly Diagnosed Glioblastoma | Sponsor not shown (see the record) | Early phase 1 | Recruiting | Glioblastoma | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07884344) |
| August 24, 2026 | NCT07781852 | Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer | Lumina Pharmaceuticals Inc | Early phase 1 | Not yet recruiting | Bladder Cancer, Glioma, Glioblastoma (GBM), Breast Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer (GC)... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07781852) |
| August 21, 2026 | NCT07778602 | Safety and Feasibility of First-line Avutometinib and Defactinib in Patients With Newly Diagnosed High-grade Gliomas | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Early phase 1 | Not yet recruiting | MGMT-unmethylated Glioblastoma (GBM), IDH Wildtype Glioblastoma | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07778602) |
| July 17, 2026 | NCT07712770 | Pilot Radioembolisation Clinical Trial Assessing Safety and Efficacy in Recurrent Glioma | Olivia Newton-John Cancer Research Institute | Early phase 1 | Not yet recruiting | Recurrent Glioblastoma IDH Wildtype, Recurrent Glioblastoma | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07712770) |
| June 15, 2026 | NCT07648823 | Dosimetry, Safety, and Efficacy Study of \[177Lu\]Lu-XT771 in Patients With Recurrent Glioblastoma | Beijing Tiantan Hospital | Early phase 1 | Recruiting | Recurrent Glioblastoma (WHO-Grade IV Glioma), Recurrent Glioblastoma, Glioblastoma (GBM), Recurrent Glioblastoma IDH... | 5 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07648823) |
| April 20, 2026 | NCT07538128 | Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent... | Huashan Hospital | Early phase 1 | Recruiting | Recurrent Glioblastoma | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07538128) |
| April 7, 2026 | NCT07515924 | Oral Gallium Maltolate for Recurrent Glioblastoma | Medical College of Wisconsin | Early phase 1 | Not yet recruiting | Glioblastoma | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07515924) |
| March 25, 2026 | NCT07493447 | Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures | Sponsor not shown (see the record) | Early phase 1 | Recruiting | Meningioma, Glioblastoma, Acoustic Neuroma, Brain Cancer, Pituitary Adenoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07493447) |
| March 20, 2026 | NCT07485049 | BGB-58067 in Newly Diagnosed Glioblastoma Patients With MTAP-Deleted Tumors | Sponsor not shown (see the record) | Early phase 1 | Recruiting | Glioblastoma (GBM) | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07485049) |
| February 4, 2026 | NCT07387666 | Imaging Acetadote Metabolism in Glioblastoma | University of Texas Southwestern Medical Center | Early phase 1 | Recruiting | Glioblastoma, GBM | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07387666) |
| December 16, 2025 | NCT07284069 | Senicapoc and Perampanel for Newly Diagnosed Glioblastoma | Aarhus University Hospital | Early phase 1 | Recruiting | Glioblastoma | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07284069) |
| December 5, 2025 | NCT07268053 | A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With... | Sponsor not shown (see the record) | Early phase 1 | Recruiting | Glioblastoma (GBM), Brain Metastasases | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07268053) |
| November 24, 2025 | NCT07244666 | Safety and Preliminary Efficacy of a Metabolically Armed Chimeric Antigen Receptor T Cell Therapy Targeting EGFRvIII for Recurrent... | Second Affiliated Hospital, Zhejiang University, School of Medicine | Early phase 1 | Not yet recruiting | Glioblastoma (GBM) | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07244666) |
| July 22, 2025 | NCT07076472 | Sonodynamic Therapy With SONALA-001 or 5-ALA HCL and Magnetic Resonance Guided Focused Ultrasound for the Treatment of Progressive or... | Mayo Clinic | Early phase 1 | Recruiting | Progressive Glioblastoma, Recurrent Glioblastoma | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07076472) |
| July 16, 2025 | NCT07067905 | Clinical Evaluation of \[68Ga\]Ga-XT771 PET for Diagnosis in Patients With Glioblastoma and Clear Cell Renal Cell Carcinoma | Chinese PLA General Hospital | Early phase 1 | Recruiting | Clear Cell Renal Cell Carcinoma and Glioblastoma | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07067905) |
| January 3, 2025 | NCT06757153 | Safety and Efficacy of NRG-103 Injection in the Treatment of Recurrent Glioblastoma Patients | Zhongnan Hospital | Early phase 1 | Recruiting | Glioblastoma (GBM) | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06757153) |
| October 17, 2024 | NCT06645808 | PET-imaging of Two Vartumabs in Patients With Solid Tumors | Var2 Pharmaceuticals | Early phase 1 | Recruiting | Solid Tumor, Colon Carcinoma, Rectal Carcinoma, Osteosarcoma, Chondrosarcoma, Lung Carcinoma, Head and Neck Squamous... | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06645808) |
| September 26, 2024 | NCT06613841 | Multitracer \[18F\]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma | Abramson Cancer Center at Penn Medicine | Early phase 1 | Recruiting | Glioblastoma, Recurrent Glioblastoma, Glioblastoma Multiforme of Brain | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06613841) |
| August 13, 2024 | NCT06552260 | A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma | Sponsor not shown (see the record) | Early phase 1 | Recruiting | Glioblastoma, Recurrent Glioblastoma, Brain Tumor | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06552260) |
| March 27, 2024 | NCT06333899 | Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion | Nationwide Children's Hospital | Early phase 1 | Recruiting | High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Infant Type Hemispheric Glioma... | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06333899) |
| October 10, 2023 | NCT06072586 | A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR... | St. Joseph's Hospital and Medical Center, Phoenix | Early phase 1 | Recruiting | High Grade Glioma, Glioblastoma | 82 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06072586) |
| June 21, 2022 | NCT05423210 | Atezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma Multiforme | Stony Brook University | Early phase 1 | Recruiting | Glioblastoma Multiforme | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05423210) |
| October 23, 2019 | NCT04135807 | Implantable Microdevice In Primary Brain Tumors | Sponsor not shown (see the record) | Early phase 1 | Recruiting | Grade II Glioma, Grade III Glioma, Grade IV Glioma, Astrocytoma, Oligodendroglioma of Brain, Anaplastic Astrocytoma of... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04135807) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Olivia Newton-John Cancer Research Institute | 2 |
| Aarhus University Hospital | 1 |
| Nationwide Children's Hospital | 1 |
| St. Joseph's Hospital and Medical Center, Phoenix | 1 |
| Beijing Tiantan Hospital | 1 |
| Stony Brook University | 1 |
| Medical College of Wisconsin | 1 |
| Var2 Pharmaceuticals | 1 |
| Chinese PLA General Hospital | 1 |
| Mayo Clinic | 1 |
| Abramson Cancer Center at Penn Medicine | 1 |
| Huashan Hospital | 1 |
| Zhongnan Hospital | 1 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 1 |
| Lumina Pharmaceuticals Inc | 1 |
| University of Texas Southwestern Medical Center | 1 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 15 |
| China | 5 |
| Australia | 3 |
| Netherlands | 2 |
| Denmark | 1 |
| Canada | 1 |
| Germany | 1 |
| New Zealand | 1 |
| Puerto Rico | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Nicaraguan restaurants in the United States](https://specstream.ai/data/businesses/nicaraguan-restaurants/united-states)
- [Whiskey bars in the United States](https://specstream.ai/data/businesses/whiskey-bars/united-states)
- [Electronic equipment suppliers in the United States](https://specstream.ai/data/businesses/electronic-equipment-suppliers/united-states)
- [Orthopedic surgery practices in the United States](https://specstream.ai/data/businesses/orthopedic-surgery-practices/united-states)
- [Abrasives suppliers in the United States](https://specstream.ai/data/businesses/abrasives-suppliers/united-states)
- [Entertainment law firms in the United States](https://specstream.ai/data/businesses/entertainment-law-firms/united-states)
